Curis, Inc. (CRIS)

1.59
NASDAQ
Prev Close 1.59
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.47 / 3.72
Exchange NASDAQ
Shares Outstanding 163.88B
Market Cap 278.59M
Div & Yield N.A. (N.A)

Latest News

Aurigene, A Wholly Owned Subsidiary Of Dr. Reddy's, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017

Aurigene, A Wholly Owned Subsidiary Of Dr. Reddy's, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017

Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr.

Curis Reports Second Quarter 2017 Financial Results

Curis Reports Second Quarter 2017 Financial Results

-- Management to host conference call today at 8:30 a.m. EDT --

Curis Reports First Quarter 2017 Financial Results

-- Management to host conference call today at 8:30 a.m. EDT --

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.

Shark Bites: We Knew Today Would Be Slow, but Come On…

Shark Bites: We Knew Today Would Be Slow, but Come On…

Don't force it; there's no energy.

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and...

Curis Reports Third Quarter 2016 Financial Results

Curis Reports Third Quarter 2016 Financial Results

Management to host conference call today at 8:30 a.m. EDT

TheStreet Quant Rating: D (Sell)